PBRM1 Immunohistochemical Expression Profile Correlates with Histomorphological Features and Endothelial Expression of Tumor Vasculature for Clear Cell Renal Cell Carcinoma.

PBRM1 architectural patterns clear cell renal cell carcinoma endothelial cells histomorphological features immunohistochemistry

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
20 Feb 2022
Historique:
received: 17 01 2022
revised: 15 02 2022
accepted: 16 02 2022
entrez: 25 2 2022
pubmed: 26 2 2022
medline: 26 2 2022
Statut: epublish

Résumé

Loss of the polybromo-1 (PBRM1) protein has been expected as a possible biomarker for clear cell renal cell carcinoma (ccRCC). There is little knowledge about how PBRM1 immunohistochemical expression correlates with the histomorphological features of ccRCC and the endothelial expression of tumor vasculature. The present study evaluates the association of architectural patterns with the PBRM1 expression of cancer cells using a cohort of 425 patients with nonmetastatic ccRCC. Furthermore, we separately assessed the PBRM1 expression of the endothelial cells and evaluated the correlation between the expression of cancer cells and endothelial cells. PBRM1 loss in cancer cells was observed in 148 (34.8%) patients. In the correlation analysis between architectural patterns and PBRM1 expression, macrocyst/microcystic, tubular/acinar, and compact/small nested were positively correlated with PBRM1 expression, whereas alveolar/large nested, thick trabecular/insular, papillary/pseudopapillary, solid sheets, and sarcomatoid/rhabdoid were negatively correlated with PBRM1 expression. PBRM1 expression in vascular endothelial cells correlated with the expression of cancer cells (correlation coefficient = 0.834,

Identifiants

pubmed: 35205810
pii: cancers14041062
doi: 10.3390/cancers14041062
pmc: PMC8870106
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : the Japan Society for the Promotion of Science KAKENHI fund
ID : 19K16875
Organisme : the Japan Society for the Promotion of Science KAKENHI fund
ID : 20K16457

Références

Mod Pathol. 2021 Nov 30;:
pubmed: 34848832
EBioMedicine. 2020 Jan;51:102526
pubmed: 31859241
Urol Oncol. 2018 Mar;36(3):94.e1-94.e14
pubmed: 29169846
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Anticancer Res. 2021 Sep;41(9):4577-4586
pubmed: 34475086
Int J Cancer. 2013 Jan 15;132(2):E11-7
pubmed: 22949125
Neoplasia. 2019 Feb;21(2):247-256
pubmed: 30660076
Nat Med. 2018 Jun;24(6):749-757
pubmed: 29867230
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Science. 2018 Feb 16;359(6377):801-806
pubmed: 29301960
Am Soc Clin Oncol Educ Book. 2020 Mar;40:1-11
pubmed: 32379987
J Pathol Clin Res. 2021 Nov;7(6):590-603
pubmed: 34212534
Cancer. 2009 May 15;115(10 Suppl):2306-12
pubmed: 19402073
N Engl J Med. 2012 Mar 8;366(10):883-892
pubmed: 22397650
Am J Surg Pathol. 2018 Apr;42(4):423-441
pubmed: 29356723
Int J Clin Oncol. 2020 Feb;25(2):338-346
pubmed: 31720994
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Urol Oncol. 2015 Aug;33(8):340.e9-16
pubmed: 26003625
Eur Urol. 2016 Jul;70(1):93-105
pubmed: 26935559
Histopathology. 2019 Feb;74(3):377-390
pubmed: 30325065
Oncotarget. 2015 Oct 13;6(31):32161-8
pubmed: 26452128
Nature. 2013 Jul 4;499(7456):43-9
pubmed: 23792563
PLoS One. 2017 Jun 27;12(6):e0179610
pubmed: 28654655
Kidney Cancer J. 2020 Sep;18(3):68-76
pubmed: 34178206
Nat Commun. 2020 May 1;11(1):2135
pubmed: 32358509
J Urol. 2016 Jan;195(1):180-7
pubmed: 26300218
Eur Urol. 2015 Jan;67(1):85-97
pubmed: 24857407
N Engl J Med. 2003 Jul 31;349(5):419-21
pubmed: 12890838
Pathol Int. 2014 May;64(5):209-16
pubmed: 24888774
J Immunother Cancer. 2021 Sep;9(9):
pubmed: 34580162
Front Oncol. 2019 Jun 14;9:490
pubmed: 31259150
Front Oncol. 2019 Dec 11;9:1400
pubmed: 31921657
JAMA Oncol. 2019 Nov 1;5(11):1631-1633
pubmed: 31486842
BJU Int. 2014 May;113(5b):E157-63
pubmed: 24053427
Nat Genet. 2012 Jun 10;44(7):751-9
pubmed: 22683710
J Immunother Cancer. 2020 Jul;8(2):
pubmed: 32661119
Ann Surg Oncol. 2021 Apr;28(4):2359-2366
pubmed: 32940805
Nature. 2011 Jan 27;469(7331):539-42
pubmed: 21248752
Clin Chim Acta. 2018 Nov;486:9-17
pubmed: 30006290

Auteurs

Kazuho Saiga (K)

Department of Pathology, Kansai Medical University, 2-3-1 Shin-machi, Hirakata 573-1191, Japan.

Chisato Ohe (C)

Department of Pathology, Kansai Medical University, 2-3-1 Shin-machi, Hirakata 573-1191, Japan.

Takashi Yoshida (T)

Department of Urology and Andrology, Kansai Medical University, 2-3-1 Shin-machi, Hirakata 573-1191, Japan.

Haruyuki Ohsugi (H)

Department of Urology and Andrology, Kansai Medical University, 2-3-1 Shin-machi, Hirakata 573-1191, Japan.

Junichi Ikeda (J)

Department of Pathology, Kansai Medical University, 2-3-1 Shin-machi, Hirakata 573-1191, Japan.
Department of Urology and Andrology, Kansai Medical University, 2-3-1 Shin-machi, Hirakata 573-1191, Japan.

Naho Atsumi (N)

Department of Pathology, Kansai Medical University, 2-3-1 Shin-machi, Hirakata 573-1191, Japan.

Yuri Noda (Y)

Department of Pathology, Kansai Medical University, 2-3-1 Shin-machi, Hirakata 573-1191, Japan.

Yoshiki Yasukochi (Y)

Department of Genome Analysis, Institute of Biomedical Science, Kansai Medical University, 2-5-1 Shin-machi, Hirakata 573-1010, Japan.

Koichiro Higasa (K)

Department of Genome Analysis, Institute of Biomedical Science, Kansai Medical University, 2-5-1 Shin-machi, Hirakata 573-1010, Japan.

Hisanori Taniguchi (H)

Department of Urology and Andrology, Kansai Medical University, 2-3-1 Shin-machi, Hirakata 573-1191, Japan.

Hidefumi Kinoshita (H)

Department of Urology and Andrology, Kansai Medical University, 2-3-1 Shin-machi, Hirakata 573-1191, Japan.

Koji Tsuta (K)

Department of Pathology, Kansai Medical University, 2-3-1 Shin-machi, Hirakata 573-1191, Japan.

Classifications MeSH